Illumina, Inc.

ILMN

US4523271090

Advanced Medical Equipment & Technology

Real-time Estimate Cboe BZX Other stock markets 11:23:05 2024-04-25 am EDT			5-day change	1st Jan Change
118.3 ^USD	-3.73%		+0.93%	-15.42%

Apr. 22	Bernstein Adjusts Price Target on Illumina to $129 From $150	MT
Apr. 22	Baird Adjusts Price Target on Illumina to $125 From $146, Neutral Rating Kept	MT

Illumina, Inc. Provides Consolidated Earnings Guidance for the Fiscal Year 2022

January 11, 2022 at 05:24 pm EST

Illumina, Inc. provided consolidated Earnings guidance for the fiscal year 2022. For the year, the company expects Consolidated GAAP diluted earnings per share of $3.03 - $3.23.

Latest news about Illumina, Inc.

Bernstein Adjusts Price Target on Illumina to $129 From $150	Apr. 22	MT
Baird Adjusts Price Target on Illumina to $125 From $146, Neutral Rating Kept	Apr. 22	MT
HSBC Adjusts Illumina Price Target to $130 From $140	Apr. 22	MT
ANALYST RECOMMENDATIONS : AMD, Colgate, Fair Isaac, Tyson Foods, AstraZeneca	Apr. 16
Baptista Research Downgrades Illumina to Hold From Buy, Adjusts PT to $149.60 From $145	Apr. 16	MT
The European Commission Approves Illumina's Plan to Divest Grail	Apr. 15	CI
Leerink Partners Adjusts Illumina's Price Target to $155 From $170	Apr. 12	MT
Illumina Secures European Commission's Approval for Grail Divestment	Apr. 12	MT
European Commission Clears Illumina's Proposed Sale of Cancer Test Maker Grail	Apr. 12	MT
EU approves Illumina's plan to divest cancer test maker Grail	Apr. 12	RE
Illumina CFO Goswami to depart, former Summit Therapeutics exec Dhingra to succeed	Apr. 09	RE
Illumina Names Ankur Dhingra as Chief Financial Officer	Apr. 09	MT
Illumina CFO Goswami to depart, Summit Therapeutics' Dhingra named successor	Apr. 09	RE
Illumina, Inc. Announces Chief Financial Officer Changes	Apr. 09	CI
Illumina, Inc. Announces Executive Changes	Apr. 09	CI
RBC Cuts Price Target on Illumina to $253 From $258, Keeps Outperform Rating	Apr. 08	MT
US Equity Markets Close Higher Thursday, Extending Gains From Wednesday	Mar. 21	MT
Illumina Shares Up After EU Court Adviser Says Antitrust Regulators Overstepped in Halting Grail Merger	Mar. 21	MT
Boost for Illumina as court adviser rejects EU merger powers	Mar. 21	RE
EU court should back Illumina's appeal against EU review of Grail deal, court adviser says	Mar. 21	RE
OTR Global Downgrades Illumina to Mixed From Positive	Mar. 20	MT
Illumina Investor Carl Icahn Withdraws Bid for Board Seat, Continues Legal Battle Over Grail Acquisition	Mar. 12	MT
Exclusive-Icahn drops Illumina board challenge threat, sources say	Mar. 12	RE
Illumina Insider Bought Shares Worth $991,672, According to a Recent SEC Filing	Feb. 26	MT
Tranche Update on Illumina, Inc.'s Equity Buyback Plan announced on February 11, 2020.	Feb. 16	CI

Illumina, Inc. specializes in the development, manufacturing and marketing of integrated systems for the analysis of genetic variation and biological function. The group's products are for genomic research centers, pharmaceutical companies, university institutions, clinical research organizations, and biotechnology companies. Net sales break down by source of income as follows: - product sales (84.1%): tools and instruments for sequencing, genotyping, genetic expression, etc.; - sales of services (15.9%). Net sales are distributed geographically as follows: the United States (52.4%), Americas (3.6%), Europe (25.3%), Asia/Pacific/Middle East/Africa (10.2%) and China/Taiwan/Hong Kong (8.5%).

Sector

Advanced Medical Equipment & Technology

Calendar

2024-05-02 - Q1 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Illumina, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

122.9 USD

Average target price

157.1 USD

Spread / Average Target

+27.87%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
ILLUMINA, INC.	-15.42%	19.57B
THERMO FISHER SCIENTIFIC	+7.64%	220B
DANAHER CORPORATION	+6.32%	185B
INTUITIVE SURGICAL, INC.	+9.42%	133B
BOSTON SCIENTIFIC CORPORATION	+26.71%	107B
SIEMENS HEALTHINEERS AG	-0.46%	62.91B
EDWARDS LIFESCIENCES CORPORATION	+13.81%	53.34B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-1.63%	47.71B
AGILENT TECHNOLOGIES, INC.	-2.98%	40.29B
GE HEALTHCARE TECHNOLOGIES INC.	+9.76%	39.57B

Other Advanced Medical Equipment & Technology

Illumina, Inc.

Equities

ILMN

US4523271090

Advanced Medical Equipment & Technology

Illumina, Inc. Provides Consolidated Earnings Guidance for the Fiscal Year 2022

Latest news about Illumina, Inc.

Chart Illumina, Inc.

Company Profile

Income Statement Evolution

Ratings for Illumina, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Advanced Medical Equipment & Technology